A cost utility and cost effectiveness analysis of different oral antiviral medications in patients with HBeAg-Negative chronic hepatitis B in Iran: an economic microsimulation decision model [PDF]
, 2016 Background: Although hepatitis B infection is the major cause of chronic liver disease in Iran, no studies have employed economic evaluations of the medications used to treat Iranian patients with chronic hepatitis B (CHB).
Alavian, Seyed Moayed +9 more
core +1 more source
Human Vaccines & Immunotherapeutics, 2019 Recently, we showed that infants with or without fetal hepatitis B e antigen (HBeAg) exposure had comparable antibody response to hepatitis B vaccination and proposed that fetal HBeAg exposure appears to not induce immunotolerance to HBV.
Hongyu Huang +7 more
doaj +1 more source
CHRONIC HEPATITIS B VIRUS INFECTION IN PREGNANCY: STRATEGIES OF ANTIVIRAL THERAPY
Alʹmanah Kliničeskoj Mediciny, 2016 Treatment of chronic hepatitis B during pregnancy is an extremely complicated issue. Despite implementation of immune prophylaxis, a significant proportion of babies born by mothers with high viral load are infected by hepatitis B virus.
P. O. Bogomolov +5 more
doaj +1 more source
Emerging Microbes and Infections, 2021 Hepatitis B e antigen (HBeAg) is a widely used marker both for chronic hepatitis B (CHB) clinical management and HBV-related basic research. However, due to its high amino acid sequence homology to hepatitis B core antigen (HBcAg), most of available anti-
Shao-Juan Wang +17 more
doaj +1 more source
Association of mutations in the basal core promoter and pre-core regions of the hepatitis B viral genome and longitudinal changes in HBV level in HBEAG negative individuals: Results from a cohort study in northern Iran [PDF]
, 2015 Background: Although certain HBV mutations are known to affect the expression of Hepatitis e antigen, their association with HBV viral level or clinical outcomes is less clear.
Besharat, S. +7 more
core +1 more source
Scientific Reports, 2021 Tenofovir and entecavir are currently designated as the preferred oral antiviral drugs for chronic hepatitis B. However, only less than 40% of patients can achieve HBeAg seroconversion.
Yu-Li Zeng +15 more
doaj +1 more source
Antiviral treatment alters the frequency of activating and inhibitory receptor-expressing natural killer cells in chronic Hepatitis B virus infected patients [PDF]
, 2012 Natural killer (NK) cells play a critical role in innate antiviral immunity, but little is known about the impact of antiviral therapy on the frequency of NK cell subsets.
Chi, X. +12 more
core +3 more sources
Blocking entry of hepatitis B and D viruses to hepatocytes as a novel immunotherapy for treating chronic infections [PDF]
, 2021 Background. Chronic hepatitis B and D virus (HBV/HDV) infections can cause cancer. Current HBV therapy using nucleoside analogues (NAs) is life-long and reduces but does not eliminate the risk of cancer.
Ahlén, G +13 more
core +1 more source
Di-san junyi daxue xuebao, 2022 Objective To analyze the clinical features of HBeAg and HBeAb double-positive patients with chronic hepatitis B, and explore the efficacy and outcomes of different antiviral regimens.
AN Xuan +6 more
doaj +1 more source
Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease [PDF]
, 2015 Hepatitis B virus (HBV) infection is a dynamic state of interactions among HBV, hepatocytes, and the host immune system. Natural history studies of chronic hepatitis B (CHB) infection have shown an association between active viral replication and adverse
Farinati, Fabio +5 more
core +1 more source